Developing Country Vaccine Manufacturers Network training partnership

Merck KGaA has a training partnership with the Developing Countries Vaccine Manufacturers Network (DCVMN).

Summary  

  • What: Merck KGaA provides educational grants and shares its expertise through its training partnership with the DCVMN, a voluntary public-health driven alliance of vaccine manufacturers.
  • Objective: The focus of the partnership is improving safety and quality in biologic manufacturing.
  • Impact: It supports the DCVMN’s goal of improving supply of and access to high quality vaccines in low-resource settings.
  • Details: The DCVMN includes over 40 vaccine manufacturers from around the world (including companies based in 11 countries in scope of the Access to Medicine Index 2016).

Merck KGaA shares its expertise on biologic manufacturing with over 40 vaccine manufacturers to support the global production of high quality vaccines through its training partnership with the Developing Countries Vaccine Manufacturers Network.

Looking closer

Merck KGaA has a training partnership with the DCVMN, a voluntary public-health driven alliance aiming to improve supply of and access to high quality vaccines in low-resource settings. The DCVMN undertakes continuing education activities for its members to support local vaccine development and production (both of which involve complex and lengthy processes).

The training partnership has been active since 2012. Through the partnership, Merck KGaA provides educational grants and shares its expertise on safety and quality in biologic manufacturing widely, with over 40 vaccine manufacturers (including companies based in 11 countries in scope of the Index), to effectively and efficiently support the global production of high quality vaccines. DCVMN members have reported the results of these capacity building initiatives to be very positive.

DCVMN members are based in the following countries in scope of the Index: Bangladesh, Brazil, China, Egypt, India, Indonesia, Iran, Mexico, South Africa, Thailand and Vietnam (as well as countries out of scope: Argentina, Cuba, South Korea, Saudi Arabia and Taiwan).

Many companies build capacity of individual third-party manufacturers in countries in scope of the Index, with whom they have a direct relationship. It is unusual to build capacity at the industry level more broadly (i.e., including with manufacturers with whom Merck KGaA does not have a commercial relationship).

Sign up to receive updates about our work.